Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study finds biologic therapies for rheumatoid arthritis not associated with increased cancer risk

05.09.2012
Largest systematic review provides the most current information on class of drugs available to patients

Biologic therapies developed in the last decade for rheumatoid arthritis are not associated with an increased risk of cancer when compared with traditional treatments for the condition, according to new research from The University of Texas MD Anderson Cancer Center.

The study, published in The Journal of the American Medical Association (JAMA), is the largest systematic review evaluating the risk of developing any malignancy among rheumatoid arthritis patients using approved biologic response modifiers (BRMs), several of which include tumor necrosis factor (TNF) inhibitors. Since 2005, conflicting data has associated TNF inhibitors with an increased risk of developing certain types of malignancies. Because of increased cases of spontaneous lymphoma in children and adolescents, the current US Food and Drug Administration warning label notes the risk of malignancy for all TNF inhibitors.

"These results are reassuring for patients considering biologic therapies for their disease," says senior author Maria E. Suarez-Almazor, M.D., professor in the Department of General Internal Medicine at MD Anderson. "Patients are understandably concerned when treatments are linked to cancer risk. With this knowledge, clinicians can effectively demonstrate that the benefits of BRMs far outweigh the risk."

Rheumatoid arthritis affects approximately one percent of the population and can lead to significant morbidity, joint deformity and impaired quality of life. Traditional treatments for rheumatoid arthritis include disease-modifying anti-rheumatic drugs (DMARDs), like methotrexate, and anti-inflammatory medications.

BRMs are prescribed as a second line of treatment if the initial DMARDs fail. BRMs target molecules on cells of the immune system and joints, and the products that are secreted in the joints, all of which can cause inflammation and joint destruction. Between 25 and 56 percent of patients use BRMs to treat the disease, but concerns over cancer risk abound because the therapies interfere with the immune system.

The researchers – part of MD Anderson's team of internal medicine specialists dedicated to treating cancer patients for medical issues other than cancer – used the Cochrane Collaboration to analyze the results of 29,423 adult patients from 63 randomized controlled trials. As a group, the trials selected compared the safety of all nine BRMs currently approved by the FDA against a placebo or traditional DMARD and included only patients with rheumatoid arthritis who had a minimum of six months of follow-up. The Cochrane Collection is an independent, non-profit organization that houses the largest collection of records of randomized controlled trials in the world.

They observed no statistically significant increased risk of any type of cancer in patients treated with BRMs compared with the other medications. In the trials analyzed, 211 patients developed a malignancy during the trial. No significant differences existed between patients in the control group who developed cancer versus those treated with BRM therapies.

"Although additional reviews of observational studies are needed to establish any long-term risk, this is a step forward in understanding overall the risk of developing cancer when taking this newer class of medication," says Suarez-Almazor. "With these results patients and clinicians can make informed decisions about treating rheumatoid arthritis."

In addition to Suarez-Almazor, other researchers contributing to the study include: Maria A. Lopez-Olivo, M.D., and Jean H. Tayar, M.D., of the Department of General Internal Medicine at MD Anderson; Stephanie Fulton, MSIS, executive director of the Research Medical Library at MD Anderson; Juan A. Martinez-Lopez, M.D., of the Spanish Society of Rheumatology; Eduardo N. Pollono, M.D., of Texas Tech University Health Science Center; Jose Polo Cueto, M.D., of Manati Medical Center (Manati, Puerto Rico); and M. Rosa Gonzales-Crespo, M.D., of the Hospital 12 de Octubre (Madrid, Spain).

Julie Penne | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Studies and Analyses:

nachricht Drone vs. truck deliveries: Which create less carbon pollution?
31.05.2017 | University of Washington

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

Im Focus: Optoelectronic Inline Measurement – Accurate to the Nanometer

Germany counts high-precision manufacturing processes among its advantages as a location. It’s not just the aerospace and automotive industries that require almost waste-free, high-precision manufacturing to provide an efficient way of testing the shape and orientation tolerances of products. Since current inline measurement technology not yet provides the required accuracy, the Fraunhofer Institute for Laser Technology ILT is collaborating with four renowned industry partners in the INSPIRE project to develop inline sensors with a new accuracy class. Funded by the German Federal Ministry of Education and Research (BMBF), the project is scheduled to run until the end of 2019.

New Manufacturing Technologies for New Products

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

A new technique isolates neuronal activity during memory consolidation

22.06.2017 | Life Sciences

Plant inspiration could lead to flexible electronics

22.06.2017 | Materials Sciences

A rhodium-based catalyst for making organosilicon using less precious metal

22.06.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>